VIENNA, Va., June 8 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) announces that it has received a letter from the American Stock
Exchange (AMEX) stating that CEL-SCI has evidenced compliance with the
requirements necessary for continued listing on the American Stock
Exchange, based on the provisions of Sections 1003(a)(1) and 1003(a)(2),
and the filings of the September 30, 2005 Form 10-K and the December 31,
2005 Form 10-Q in accordance with 134 and 1101 of the AMEX Company Guide.
CEL-SCI's continuing listing eligibility will be assessed on an ongoing
basis.
CEL-SCI Corporation is developing new immune system-based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
COMPANY: Gavin de Windt of CEL-SCI
Corporation, +1-703-506-9460; INVESTOR RELATIONS: Mike Lucci of
Lucci Financial Group, LLC, +1-248-723-3330, for CEL-SCI
Corporation
|
